OptimumBank Holdings, Inc. Form 8-K Summary
Business Context and Reporting Period
OptimumBank Holdings, Inc. (OPHC), a Florida corporation, filed this Current Report on Form 8-K dated March 28, 2024. The filing discloses a material definitive agreement and unregistered sales of equity securities executed on the same date.
Key Financial Metrics and Transaction Details
The Company completed a private placement transaction with the following specifics:
- Gross Proceeds: $7,942,997
- Common Stock Issued: 1,511,025 shares
- Series C Preferred Stock Issued: 525,641 shares
- Price Per Share: $3.90
- Number of Investors: 6
- Placement Agent: Compass Point Research and Trading, LLC
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity metrics as this report focuses on a specific capital raise event rather than periodic financial performance.
Material Changes and Corporate Actions
In connection with the issuance of Series C preferred stock, the Company adopted articles of amendment to its Articles of Incorporation to authorize and designate the new series. Additionally, registration rights agreements were entered into with five of the six investors, requiring the registration of 1,381,025 shares of common stock under the Securities Act of 1933.
Use of Proceeds and Outlook
Management intends to use the gross proceeds from the offering to pay operating expenses or to contribute capital to OptimumBank to support its growth and operations. The shares were issued in reliance on the exemption from registration set forth in Section 4(a)(2) of the Act and Rule 506.
Investor Verification Checklist
- Verify the specific terms and liquidation preferences of the newly authorized Series C preferred stock in Exhibit 3.1.
- Confirm the impact of the 1,381,025 shares subject to registration rights on future dilution.
- Review the Placement Agent Agreement (Exhibit 10.3) for details on fees and commissions paid to Compass Point Research and Trading, LLC.
- Assess the Company's current capital adequacy and liquidity position following the $7.9 million infusion.